eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | hepatitis c |
| Symptom | |chronic infection |
| Sentences | 115 |
| PubMedID- 24175062 | chronic infection with hepatitis c virus (hcv) is treated with a combined therapy of peginterferon-α-2a (pegifn-α-2a) or pegifn-α-2b and ribavirin. |
| PubMedID- 24713004 | chronic infection with hepatitis c virus (hcv) is a leading indicator for liver disease. |
| PubMedID- 22947522 | chronic infection with hepatitis c virus (hcv) is a major and growing public health concern worldwide, including in latin america. |
| PubMedID- 26429337 | chronic infection with hepatitis c virus (chc) is a large public health problem, impacting an estimated three million people in the united states . |
| PubMedID- 21407274 | The prevalence of chronic infection with the hepatitis c virus (hcv) in patients with chronic kidney disease is higher than in the general population. |
| PubMedID- 26357610 | chronic infection with hepatitis c virus (hcv) is estimated to affect approximately 3% of the world's population and cause 350,000 deaths each year. |
| PubMedID- 24273918 | Background: the rate of hepatocellular carcinoma (hcc) is increasing in egypt where the major risk factor is chronic infection with hepatitis c virus (hcv). |
| PubMedID- 22966221 | chronic infection with the hepatitis c virus (hcv) is a major risk factor for the development of hepatocellular carcinoma (hcc). |
| PubMedID- 24717818 | An estimated 3.2 million persons in the united states have chronic infection with hepatitis c virus (hcv). |
| PubMedID- 24695489 | The egyptian population has a heavy burden of liver disease, mostly due to chronic infection with hepatitis c virus . |
| PubMedID- 22899946 | chronic infection with hepatitis c virus (hcv), a hepatotropic and lymphotropic agent, is a growing global health issue affecting an estimated 170 million people 1. |
| PubMedID- 24685721 | Background & aims: production of interferon (ifn)-gamma by natural killer (nk) cells is attenuated during chronic infection with hepatitis c virus (hcv). |
| PubMedID- 25814250 | Approximately 3% of the worlds population suffers from chronic infections with hepatitis c virus (hcv). |
| PubMedID- 20513077 | Case report: cure of chronic infection with hepatitis c virus after 6 weeks of peg-interferon and ribavirin in a patient co-infected with hiv. |
| PubMedID- 23291588 | chronic infection with hepatitis c virus (hcv) is a common cause of liver cirrhosis and cancer. |
| PubMedID- 21326840 | chronic infection with hepatitis c virus is estimated to affect almost 4 million people in the usa, 5 million in europe, and 170 million worldwide 1. |
| PubMedID- 24984340 | Recently approved direct-acting antiviral agents (daa) for the treatment of chronic infection with hepatitis c virus (hcv) genotype 1, protease inhibitors (pi) boceprevir and telaprevir, have substantially increased the rates of sustained virologic response in the treatment of naive and experienced patients. |
| PubMedID- 26034765 | Overall, liver-related death, mainly due to chronic infection with hepatitis c virus (hcv) or hepatitis b virus, represents the most frequent cause of non-aids-related death 2. |
| PubMedID- 24114816 | Background and rationale: chronic infection with the hepatitis c virus (hcv) is associated with a higher prevalence of insulin resistance compared to the general population. |
| PubMedID- 22848445 | chronic infection with the hepatitis c virus (hcv) affects an estimated 2–3% of the world's population and is a leading cause of cirrhosis and hepatocellular carcinoma 1. |
| PubMedID- 26186636 | chronic infection with the hepatitis c virus (hcv) is a cause of cirrhosis and hepatocellular carcinoma worldwide. |
| PubMedID- 24925642 | The aim of the present study was to measure the influence of chronic infection with viral hepatitis c (chc) genotype 1 and 4 on serum levels of activin-a, activin-b and follistatin, and to determine their correlations with viral load, liver damage, interleukin-6 (il-6) and tumour necrosis factor (tnf)-alpha. |
| PubMedID- 22925702 | chronic infection with hepatitis c virus (hcv) is one of the leading causes of chronic liver disease; about 170 million people worldwide are estimated to be infected. |
| PubMedID- 24839620 | Background: chronic infection with hepatitis c virus (hcv) is a major cause of cirrhosis, hepatocellular carcinoma and liver transplantation. |
| PubMedID- 26424404 | chronic infection with hepatitis c virus (hcv) has emerged as a significant contributor to morbidity and mortality in patients infected with human immunodeficiency virus (hiv) in the era of successful antiretroviral therapy (art) implementation . |
| PubMedID- 21994696 | chronic infection with hepatitis c virus (hcv) is associated with significant liver disease and is therefore an important public health problem. |
| PubMedID- 21183794 | chronic infection with hepatitis c virus (hcv) is a major public health problem, with nearly 170 million infected individuals worldwide. |
| PubMedID- 24631092 | hepatitis c virus (hcv) leads to chronic infection in the majority of infected patients presumably due to failure or inefficiency of the immune responses generated. |
| PubMedID- 20173735 | chronic infection with the hepatitis c virus (hcv) affects 170 million people worldwide and is an important cause of liver-related morbidity and mortality. |
| PubMedID- 22648263 | Obermayer-straub and manns emphasized that chronic infections with hepatitis c virus (hcv) are associated with various autoimmune manifestations, including mixed cryoglobulinemia, membranoproliferative glomerulonephritis, autoimmune thyroid diseases, sporadic porphyria, cutanea tarda and b-cell lymphoma. |
| PubMedID- 20974315 | Background: the standard treatments for chronic infection with the hepatitis c virus (hcv) are peginterferon alpha-2a or alpha-2b plus ribavirin, but it remains unclear if one has a better efficacy and safety profile. |
| PubMedID- 20950406 | chronic infection with the hepatitis c virus (hcv) is more prevalent than human immunodeficiency virus (hiv) infection, but more public health resources are allocated to hiv than to hcv. |
| PubMedID- 22187946 | chronic infection with hepatitis c virus (hcv), mainly genotype 1, has been shown to be associated with insulin resistance and type 2 diabetes. |
| PubMedID- 25893197 | chronic infection with hepatitis c virus negatively regulates both the innate and adaptive arms of the immune system. |
| PubMedID- 21316532 | Background: cirrhosis developing during chronic infection with the hepatitis c virus (hcv) poses a risk of anticipated liver-related death, therefore representing a dominant indication to anti-hcv therapy. |
| PubMedID- 24609763 | chronic infection with hepatitis c virus (hcv) often affects the b-cell compartment, leading to the occurrence of autoimmunity and b-cell lymphoproliferation, in particular mixed cryoglobulinemia and b-cell lymphomas. |
| PubMedID- 22534629 | Background: chronic infection with hepatitis c virus (hcv) is associated with failures of t-cell-mediated immune clearance and with abnormal b-cell growth and activation. |
| PubMedID- 21870716 | chronic infection with hepatitis c virus is nowadays responsible for many cases of liver disease. |
| PubMedID- 20813419 | Background & aims: chronic infection with hepatitis c virus (hcv) is often associated with elevated hepatic iron levels. |
| PubMedID- 23936821 | chronic infection with hepatitis c virus (hcv) affects almost 200 million people worldwide, representing a leading cause of cirrhosis and anticipated liver-related death 1. |
| PubMedID- 25013557 | chronic infection with hepatitis c virus (hcv) continues to be the most common indication for orthotopic liver transplantation (olt) in the united states and western europe. |
| PubMedID- 22537438 | Recently developed drugs and innovative strategies for the treatment of chronic infection with genotype 1 hepatitis c virus (hcv) have become the standard of care. |
| PubMedID- 25820703 | Background: chronic infection with hepatitis c virus (hcv) genotype 2 or 3 can be treated with sofosbuvir without interferon. |
| PubMedID- 20557368 | Two week induction of interferon-beta followed by pegylated interferon alpha-2b and ribavirin for chronic infection with hepatitis c. |
| PubMedID- 25579804 | Continuous hepatic inflammation as a result of chronic infection with the hepatitis c virus may lead to the development of fibrosis and eventually cirrhosis. |
| PubMedID- 23230035 | Purpose: the pharmacologic properties, clinical efficacy, and safety profile of the first oral protease inhibitor approved for the treatment of chronic infection with hepatitis c virus (hcv) genotype 1 are reviewed. |
| PubMedID- 23226039 | chronic infection with hepatitis c virus (hcv) is a major public health problem, with perhaps 180 million people infected worldwide. |
| PubMedID- 25314116 | Historically, clinical trials of regimens to treat chronic infection with hepatitis c virus (hcv) have used, as their primary efficacy endpoint, a sustained virological response (svr)-defined as hcv rna levels below a designated threshold of quantification-24 weeks after the end of treatment (svr24). |
| PubMedID- 21576430 | chronic infection with hepatitis c virus (hcv) is a major global health burden and is associated with an increased risk of liver cirrhosis and hepatocellular carcinoma. |
| PubMedID- 25476473 | During the interview reported treatment of chronic infection with hepatitis c virus (hcv) with peginterferon and ribavirin. |